“My Heart Tests Are Normal, So Why Am I Out of Breath?” The Hidden Crisis Behind Perfect Reports

Key Takeaway: Heart Failure with Preserved Ejection Fraction (HFpEF) shatters the conventional cardiology paradigm by demonstrating that a patient can experience severe, progressive congestive heart failure even with a perfectly normal systolic pumping capacity (ejection fraction at 60 percent or higher). Rather than a mechanical failure of contraction, this complex systemic syndrome represents a hidden crisis of relaxation mechanics and microvascular endothelial inflammation, driven heavily by comorbid metabolic burdens like obesity, diabetes, and kidney disease. Chronic inflammatory cytokines systematically target the coronary capillary endothelium, disrupting the crucial eNOS-cGMP-PKG signaling pathway and leaving the master elastic spring protein, titin, aberrantly phosphorylated into a rigid, unyielding molecular isoform. This cellular stiffening, compounded by uncontrolled extracellular matrix collagen fibrosis, elevates left ventricular filling pressures and forces fluid to pool backward into the lungs, producing profound shortness of breath. Overcoming this diagnostic challenge requires meticulous clinical phenotyping using multi-tiered scoring systems (HFA-PEFF and H2FPEF) and implementing a modern multi-disciplinary therapeutic approach centered on the proven cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists to mitigate microvascular inflammation, preserve tissue flexibility, and dramatically reduce hospitalization risk.

Introduction: The Danger Hidden Behind Contractile Strength

For many years, classical cardiology teaching equated heart failure almost exclusively with the inability of the left and right ventricles—the muscular chambers of the heart that pump blood to the entire body and the lungs—to contract, their subsequent dilation, and a drop in ejection fraction (EF), which represents the contractile or pumping power (HFrEF). For a long time, clinical practice focused heavily on treating this mechanical deficit. Today, however, nearly half of the heart failure presentations encountered in outpatient clinics and clinical rounds completely challenge this conventional framework. Patients present with classic congestive heart failure symptoms such as progressive shortness of breath, pronounced edema on the anterior surface of the lower legs (pretibial edema), exercise intolerance, and jugular venous distension; yet, upon echocardiographic evaluation, the contractile strength of the left ventricle—the ejection fraction—appears at 60 percent or higher, which is considered completely “normal.”

This represents the greatest and most insidious paradox in modern cardiovascular medicine: Heart Failure with Preserved Ejection Fraction (HFpEF). The fact that the heart’s systolic contractile strength is intact does not mean it can adequately nourish tissues or that intracardiac pressures are within normal limits. Historically oversimplified as “diastolic heart failure,” this clinical entity is a far more complex systemic syndrome driven by underlying metabolic, inflammatory, and microvascular mechanisms. HFpEF must be evaluated as a hemodynamic condition where the heart fails to meet the body’s circulatory demands or does so only at the expense of elevated left ventricular filling pressures. Therefore, the “final common pathway” for the development of fluid accumulation (congestion) in the body can be summarized as follows: increased left ventricular end-diastolic pressure, left atrial hypertension, fluid accumulation in the pulmonary veins, and expansion of plasma volume. These targets are critically important in the treatment of heart failure with preserved ejection fraction (HFpEF).

In this comprehensive analysis, we will deeply examine the heart’s relaxation mechanics, cellular stiffness processes, coronary microvascular dysfunction, and the new therapeutic paradigms in the clinical management of this hidden crisis of flexibility.

The Unrelaxing Heart: The Mechanical Conflict Between Systolic Power and Diastolic Resistance

At its core, HFpEF is not a problem of the heart’s “pumping” ability, but a problem of “filling and relaxation.” While the left ventricular muscle cells (cardiomyocytes) successfully fulfill their duty of ejecting blood into the aorta during systole, they fail to relax and ease open during that vital phase between two contractions: diastole. Diastole is not a passive and ordinary deflation event; on the contrary, it is an active process that actively pumps calcium back into the cellular stores and consumes a massive amount of the energy molecule ATP (Adenosine Triphosphate).

• The Hydraulics of High Filling Pressures: When the heart muscle loses its elasticity and compliance (its capacity to adapt to volume), it requires much higher hydraulic pressure to force clean blood coming from the lungs into the left ventricle. This elevated left ventricular end-diastolic pressure (LVEDP) reflects backward as a passive wave. It first dilates the left atrium (leading to left atrial hypertension) and then propagates through the pulmonary veins, causing pooling in the pulmonary capillary bed (pulmonary congestion). As a result, the patient experiences severe shortness of breath (dyspnea), feeling as though they are suffocating, particularly during exertion or when lying flat (orthopnea).
• Titin Protein and the Molecular Basis of Cellular Stiffness: At the cellular level, this loss of elasticity is governed by a protein named titin, which functions like a microscopic mechanical spring within the sarcomere. Titin is the master molecule determining how much the heart stretches during diastole and how it recoils during systole. It exists in two primary isoforms: the stiffer N2B and the more compliant N2BA. In HFpEF patients, chronic metabolic stress and inflammation disrupt intracellular signaling pathways; specifically, protein kinase G (PKG) activity is blunted, while protein kinase C (PKC) activity surges. This mismatch leads to the aberrant phosphorylation of titin, favoring the rigid N2B isoform over the flexible N2BA. Consequently, the heart muscle transforms at a cellular level into a stiff, unyielding steel spring.
• Extracellular Matrix Remodeling and Fibrosis: The defect extends beyond intracellular proteins. Within the interstitial space, activated myofibroblasts begin synthesizing Type I collagen at an uncontrolled rate. As the cross-linking of these collagen fibers intensifies, the ventricular wall becomes biomechanically rigid. The heart can no longer stretch gently to accommodate incoming blood.

Microvascular Inflammation: The Hidden Signaling Network Squeezing the Heart

Modern pathophysiological models have moved away from viewing HFpEF merely as a localized, primary myocardial disease. Today, the most widely accepted paradigm (the Paulus and Tschöpe model) defines it as a systemic microvascular endothelial inflammation.

• The Inflammatory Burden of Comorbidities: Virtually all HFpEF patients present with systemic metabolic burdens such as obesity, type 2 diabetes, chronic kidney disease, arterial hypertension, and obstructive sleep apnea. These conditions exist either individually or concurrently. These chronic diseases fuel a continuous, low-grade systemic inflammatory cascade characterized by elevated circulating cytokines like interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta.
• Coronary Capillary Endothelium and the Collapse of the cGMP-PKG Pathway: Traveling through the bloodstream, these pro-inflammatory cytokines target the endothelium—the inner lining of the tiny capillary vessels nourishing the heart. Endothelial cells begin expressing adhesion molecules (VCAM-1, ICAM-1), throwing the function of the endothelial nitric oxide synthase (eNOS) enzyme into disarray. As the bioavailability of Nitric Oxide (NO) plummets, the neighboring cardiomyocytes experience a failure in the activation of the soluble guanylyl cyclase (sGC) enzyme, causing intracellular cyclic guanosine monophosphate (cGMP) levels to drop. This depletion of cGMP leaves Protein Kinase G (PKG)—the enzyme responsible for keeping titin compliant—entirely nonfunctional. Thus, microvascular inflammation within the vessels directly stiffens the cardiac muscle cells. Unless this insidious inflammatory chain is broken, reversing the patient’s congestive heart failure symptoms remains difficult.

“The Football vs. Basketball Paradox”

In the outpatient clinic, under constant time pressure, healthcare providers and patients alike often fall prey to a single metric: the Ejection Fraction (or contractile power). Patients frequently walk in holding a clean echocardiography report, asking: “Doctor, my heart’s pumping power is at 65 percent. The report says there are no valve issues or enlargement. So why do I run out of breath after just two flights of stairs? Why do I wake up gasping for air at night?”

To explain this complex hydraulic breakdown, I always use a concrete analogy:

“Imagine you are holding two different balls in your hands. One is a soft, high-quality, flexible football; the other is a brand-new basketball, inflated to its limit until it is as hard as stone. When you squeeze and release both balls (resembling the heart squeezing to fling blood during systole), both will expel the air inside with the exact same immense force. That 65 percent efficiency on your echo represents this throwing ability. But our job doesn’t end there. Now, think about letting go of those balls and trying to refill them with water or air from the outside (resembling the heart’s filling phase during diastole). The flexible football expands without resistance and takes the water right in. But if you want to expand that rock-hard basketball to fill it, you must apply tremendous pressure from the outside. Right now, your heart has turned into that rigid basketball. Its contraction is flawless, but it cannot relax or stretch to receive blood. Because the blood coming from your lungs cannot easily enter your heart, it pools backward, leaving you completely breathless.”

As clinicians, our duty is not simply to look at how hard the heart can strike during systole and send the patient home. The peace of the tissues and the patient’s quality of life depend just as much on how gracefully, flexibly, and generously the heart can open up during diastole. We must treat the mechanical flexibility of the tissue, not just the numbers on a screen.

Diagnostic Algorithms and Phenotyping Challenges

Diagnosing HFpEF is one of the most challenging processes in cardiology because a resting echocardiogram can easily fall within normal limits. Therefore, the diagnostic approach must be multi-tiered and meticulous.

• The HFA-PEFF Algorithm and the H2FPEF Score: The European Society of Cardiology (ESC) developed the HFA-PEFF algorithm to standardize diagnosis. This system scores functional parameters (tissue Doppler measurements, E/e’ ratio), morphological features (left atrial volume index, left ventricular mass index), and biomarkers (NT-proBNP or BNP levels). Similarly, the H2FPEF score, which relies entirely on clinical criteria (Obesity, Hypertension, Atrial Fibrillation, Pulmonary Hypertension, Age, and Filling Pressures), allows us to quickly perform risk stratification right in the clinic.
• Stress Echocardiography and Invasive Hemodynamic Testing: In patients whose symptoms are absent or borderline at rest, assessing how left ventricular filling pressures (PCWP – pulmonary capillary wedge pressure) elevate during exertion via stress echocardiography or right heart catheterization remains the gold standard to confirm the diagnosis. However, performing stress echocardiography under outpatient clinic conditions is difficult. Furthermore, it requires experienced doctors and personnel. Right heart catheterization, on the other hand, is an invasive procedure and is not recommended unless absolutely necessary.
• How Should the Diagnosis Be Made? Current research indicates that there are approximately five million heart failure patients in the United States. About half of these patients suffer from heart failure with preserved ejection fraction (HFpEF). It appears to be more prevalent in women and the elderly population. We must keep this vital fact in mind: the diagnosis of heart failure is primarily established based on the patient’s complaints and physical examination findings. If suspected, accompanying comorbidities must be taken into consideration. Subsequently, if feasible, an echocardiogram should be performed. If the ejection fraction (contractile power) is normal, other parameters on the echocardiogram should be examined, and NT-proBNP and BNP tests should be evaluated as diagnostic aids.

New Paradigms in Treatment: The Triumph of SGLT2 Inhibitors

Until recently, HFpEF was known as the most difficult-to-treat disease in cardiology because therapies that successfully reduced mortality in HFrEF—such as ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists (MRAs)—failed to achieve statistically significant success regarding overall mortality in major HFpEF clinical trials. However, recent years have brought a total paradigm shift.

• SGLT2 Inhibitors (Empagliflozin and Dapagliflozin): Massive randomized controlled clinical trials, such as EMPEROR-Preserved and DELIVER, proved that SGLT2 inhibitors significantly reduce the risk of cardiovascular death and hospitalization for heart failure in HFpEF patients. By blocking sodium and glucose reabsorption in the kidneys, these agents promote natriuresis, thereby lowering preload. Crucially, they go beyond simple diuresis; they mitigate systemic inflammation, modulate myocardial sodium-hydrogen exchange, and optimize the mitochondrial energy efficiency of the heart muscle. These drugs are actually diabetes medications. Patients might occasionally object, stating, “I don’t have diabetes.” In such cases, it is necessary for the physician to explain to the patient exactly why we are utilizing these medications for cardiac protection.
• A Multidisciplinary Approach: Achieving optimal volume control with loop diuretics, slowing myocardial fibrosis with MRAs (Spironolactone), and incorporating weight management via GLP-1 receptor agonists if obesity is a comorbidity are now indispensable pillars of comprehensive therapy. Special emphasis must be placed on weight loss injections. Numerous clinical trials have demonstrated that weight loss injections, such as semaglutide and tirzepatide, offer significant therapeutic benefits in heart failure management.

Conclusion: The Deep Resilience of the Heart

We must fundamentally alter our clinical perspective on heart failure management. A preserved ejection fraction is not a guarantee that a patient’s vascular and myocardial systems are safe. The future of cardiology lies beyond macro-mechanical measurements; it will focus on protecting the microvascular endothelium, revitalizing the eNOS-cGMP-PKG pathway, and extinguishing tissue-level inflammation. The biological success of the heart is measured not just by how far it can hurl blood, but by how well it can yield and expand to receive life and blood itself.

Our Slogan: “Your heart’s health may be hidden in its power to contract, but your life’s comfort is secured by its flexibility to relax.”

Key Clinical Studies & Guidelines Reviewed

1. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297-3317.
2. Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Diagnose Heart Failure With Preserved Ejection Fraction: The H2FPEF Score. Circulation. 2018;138(9):861-870.
3. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021;385(16):1451-1461.
4. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. 2022;387(12):1089-1098.
5. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263-271.
6. Mylonas N, Nikolaou P, Karakasis P, Stachteas P, Fragakis N, Andreadou I. Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies. International Journal of Molecular Sciences. 2024;25.

 

Share this article

LinkedIn X Facebook WhatsApp Copy Link